A patient suffering from retinal vein occlusion can read again. This breakthrough happened at Leuven University Hospital, thanks to a robot, an ultra thin needle and a medicine made by Leuven-based ThromboGenics.
The blood vessels in the eye are as thin as a human hair, making it impossible for a human hand to insert a needle without causing massive damage. But a robot, operated by a surgeon and equipped with an ultra thin needle, makes this task a whole lot easier. The medicine used, Ocriplasmine, is made by Leuven-based biotech company ThromboGenics.
The robot is the result of years of work done by researchers from Leuven. The technology combined with the medicine offers a cheaper solution to 16 million people worldwide who suffer from Retinal Vein Occlusion.